VivoSim Labs | 10-Q: FY2026 Q2 Revenue: USD 28 K

Revenue: As of FY2026 Q2, the actual value is USD 28 K.

EPS: As of FY2026 Q2, the actual value is USD -0.98.

EBIT: As of FY2026 Q2, the actual value is USD -2.727 M.

Royalty Revenue: $28,000 for the three months ended September 30, 2025, and $28,000 for the same period in 2024. For the six months ended September 30, 2025, royalty revenue was $65,000, compared to $53,000 for the same period in 2024.
Product Revenue: $0 for the three months ended September 30, 2025, compared to $2,000 for the same period in 2024. For the six months ended September 30, 2025, product revenue was $0, compared to $16,000 for the same period in 2024.

Net Loss: -$2.5 million for the three months ended September 30, 2025, compared to -$2.5 million for the same period in 2024. For the six months ended September 30, 2025, net loss was -$5.4 million, compared to -$5.9 million for the same period in 2024.
Research and Development Expenses: $923,000 for the three months ended September 30, 2025, compared to $984,000 for the same period in 2024. For the six months ended September 30, 2025, R&D expenses were $1.9 million, compared to $2.4 million for the same period in 2024.
Selling, General and Administrative Expenses: $1.7 million for the three months ended September 30, 2025, compared to $1.7 million for the same period in 2024. For the six months ended September 30, 2025, SG&A expenses were $3.7 million, compared to $3.7 million for the same period in 2024.

Operating Cash Flow: -$6.3 million for the six months ended September 30, 2025, compared to -$5.6 million for the same period in 2024.
Net Cash Provided by Financing Activities: $1.7 million for the six months ended September 30, 2025, compared to $5.9 million for the same period in 2024.

Core Business Focus: VivoSim Labs, Inc. plans to continue advancing its Preclinical IBD Program with the goal of having a product candidate ready for an Investigational New Drug (IND) application with the FDA by December 2026. The company is also focusing on offering liver toxicology predictive screening and research services, as well as studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
Non-Core Business: The company sold its FXR program for $10.0 million in March 2025, with $9.0 million paid at closing and $1.0 million held in escrow for 15 months. Future milestones of up to $50.0 million in aggregate may be paid if the asset, FXR314, hits key development, regulatory, and commercial milestones.
Priority: The company is prioritizing the development of its liver and intestinal toxicology insights using its NAM models, which are expected to gain accelerated adoption following the FDA’s announcement to refine animal testing requirements in favor of non-animal NAM methods.